Works matching IS 01676997 AND DT 2023 AND VI 41 AND IP 2

Results: 20

SLIT mutations as potential predictive biomarkers for immunotherapy in NSCLC.

Published in:

2023

By:

Zhou, Tong;
Yi, Huan;
Zhu, Chan;
Yu, Yangyang;
He, Qianru;
Xiao, Mingzhe;
Qi, Chuang;
Lu, Tianyu

Publication type:

Letter

Development of a MET-targeted single-chain antibody fragment as an anti-oncogene targeted therapy for breast cancer.

Published in:

Investigational New Drugs, 2023, v. 41, n. 2, p. 226, doi. 10.1007/s10637-023-01354-7

By:

Vafaei, Rana;
Khaki, Zohreh;
Salehi, Malihe;
Jalili, Neda;
Esmailinejad, Mohammad Reza;
Muhammadnajad, Ahad;
Nassiri, Seyed Mahdi;
Vajhi, Alireza;
Kalbolandi, Shima Moradi;
Mirzaei, Roya;
Farahmand, Leila

Publication type:

Article

Immunohistochemical analysis of B7-H3 expression in patients with lung cancer following various anti-cancer treatments.

Published in:

Investigational New Drugs, 2023, v. 41, n. 2, p. 356, doi. 10.1007/s10637-023-01353-8

By:

Omori, Shota;
Muramatsu, Koji;
Kawata, Takuya;
Miyawaki, Eriko;
Miyawaki, Taichi;
Mamesaya, Nobuaki;
Kawamura, Takahisa;
Kobayashi, Haruki;
Nakashima, Kazuhisa;
Wakuda, Kazushige;
Ono, Akira;
Kenmotsu, Hirotsugu;
Naito, Tateaki;
Murakami, Haruyasu;
Sugino, Takashi;
Takahashi, Toshiaki

Publication type:

Article

Mesenchymal stem cells: a trojan horse to treat glioblastoma.

Published in:

Investigational New Drugs, 2023, v. 41, n. 2, p. 240, doi. 10.1007/s10637-023-01352-9

By:

Chartouni, Antoine;
Mouawad, Antoine;
Boutros, Marc;
Attieh, Fouad;
Medawar, Nicolas;
Kourie, Hampig Raphaël

Publication type:

Article

Iruplinalkib (WX‑0593), a novel ALK/ROS1 inhibitor, overcomes crizotinib resistance in preclinical models for non-small cell lung cancer.

Published in:

Investigational New Drugs, 2023, v. 41, n. 2, p. 254, doi. 10.1007/s10637-023-01350-x

By:

Yang, Yingying;
Zheng, Qingmei;
Wang, Xinmei;
Zhao, Shuyong;
Huang, Wenshu;
Jia, Linchao;
Ma, Cuicui;
Liu, Shicong;
Zhang, Yongpeng;
Xin, Qianqian;
Sun, Yan;
Zheng, Shansong

Publication type:

Article

Effects on survival of the adverse event of atezolizumab plus bevacizumab for hepatocellular carcinoma: a multicenter study by the Japan Red Cross Liver Study Group.

Published in:

Investigational New Drugs, 2023, v. 41, n. 2, p. 340, doi. 10.1007/s10637-023-01349-4

By:

Takaki, Shintaro;
Kurosaki, Masayuki;
Mori, Nami;
Tsuji, Keiji;
Ochi, Hironori;
Marusawa, Hiroyuki;
Nakamura, Shinichiro;
Tada, Toshifumi;
Narita, Ryoichi;
Uchida, Yasushi;
Akahane, Takehiro;
Kondo, Masahiko;
Kusakabe, Atsunori;
Furuta, Koichiro;
Kobashi, Haruhiko;
Arai, Hirotaka;
Nonogi, Michiko;
Tamada, Takashi;
Hasebe, Chitomi;
Ogawa, Chikara

Publication type:

Article

Clinical characteristics, treatment and outcome of nivolumab-induced myasthenia gravis.

Published in:

Investigational New Drugs, 2023, v. 41, n. 2, p. 333, doi. 10.1007/s10637-023-01347-6

By:

Wang, Chunjiang;
Zeng, Hanqing;
Fang, Weijin;
Song, Liying

Publication type:

Article

Anticancer effect of zanubrutinib in HER2-positive breast cancer cell lines.

Published in:

Investigational New Drugs, 2023, v. 41, n. 2, p. 210, doi. 10.1007/s10637-023-01346-7

By:

Dostálová, Hana;
Jorda, Radek;
Řezníčková, Eva;
Kryštof, Vladimír

Publication type:

Article

A tumor-selective adenoviral vector platform induces transient antiphospholipid antibodies, without increased risk of thrombosis, in phase 1 clinical studies.

Published in:

Investigational New Drugs, 2023, v. 41, n. 2, p. 317, doi. 10.1007/s10637-023-01345-8

By:

Khalil, Danny N.;
Prieto González-Albo, Isabel;
Rosen, Lee;
Lillie, Tom;
Stacey, Andrea;
Parfitt, Lola;
Soff, Gerald A.

Publication type:

Article

RNA silencing of GM-CSF in CAR-T cells reduces the secretion of multiple inflammatory cytokines.

Published in:

Investigational New Drugs, 2023, v. 41, n. 2, p. 220, doi. 10.1007/s10637-023-01344-9

By:

Shang, Siqi;
Chen, Yunshuo;
Yang, Xuejiao;
Yang, Ying;
Wang, Wenbo;
Wang, Yueying

Publication type:

Article

Effective anticancer agents based-on two Pillar[5]arene derivatives for pancreas cancer cell lines: synthesis, apoptotic effect, caspase pathway.

Published in:

Investigational New Drugs, 2023, v. 41, n. 2, p. 202, doi. 10.1007/s10637-023-01343-w

By:

Karaselek, Mehmet Ali;
Kuccukturk, Serkan;
Duran, Tugce;
Kursunlu, Ahmed Nuri;
Ozmen, Mustafa;
Bozdag, Ceren;
Alkan, Selman;
Varman, Alper;
Yildirim, Mehmet Aykut;
Kucukkartallar, Tevfik;
Vatansev, Celalettin

Publication type:

Article

Phase 1 study to determine the safety and dosing of autologous PBMCs modified to present HPV16 antigens (SQZ-PBMC-HPV) in HLA-A*02+ patients with HPV16+ solid tumors.

Published in:

Investigational New Drugs, 2023, v. 41, n. 2, p. 284, doi. 10.1007/s10637-023-01342-x

By:

Jimeno, Antonio;
Baranda, Joaquina;
Iams, Wade T.;
Park, Jong Chul;
Mita, Monica;
Gordon, Michael S.;
Taylor, Matthew;
Dhani, Neesha;
Leal, Alexis D.;
Neupane, Prakash;
Eng, Cathy;
Yeku, Oladapo;
Mita, Alain;
Moser, Justin C.;
Butler, Marcus;
Loughhead, Scott M.;
Jennings, Julia;
Miselis, Nathan R.;
Ji, Rui-Ru;
Nair, Nitya

Publication type:

Article

Evaluation of combination treatment with DS-1205c, an AXL kinase inhibitor, and osimertinib in metastatic or unresectable EGFR-mutant non-small cell lung cancer: results from a multicenter, open-label phase 1 study.

Published in:

Investigational New Drugs, 2023, v. 41, n. 2, p. 306, doi. 10.1007/s10637-023-01341-y

By:

Yang, James Chih-Hsin;
Su, Wu-Chou;
Chiu, Chao-Hua;
Shiah, Her-Shyong;
Lee, Kang-Yun;
Hsia, Te-Chun;
Uno, Makiko;
Crawford, Nigel;
Terakawa, Hiroshi;
Chen, Wen-Chi;
Takayama, Gensuke;
Hsu, Ching;
Hong, Ying;
Saintilien, Carline;
McGill, Joseph;
Chang, Gee-Chen

Publication type:

Article

A phase 1b study of the allosteric extracellular FGFR2 inhibitor alofanib in patients with pretreated advanced gastric cancer.

Published in:

Investigational New Drugs, 2023, v. 41, n. 2, p. 324, doi. 10.1007/s10637-023-01340-z

By:

Tsimafeyeu, Ilya;
Statsenko, Galina;
Vladimirova, Liubov;
Besova, Natalia;
Artamonova, Elena;
Raskin, Grigory;
Rykov, Ivan;
Mochalova, Anastasia;
Utyashev, Igor;
Gorbacheva, Svetlana;
Kazey, Vasily;
Gavrilova, Evgenia;
Dragun, Nadezhda;
Moiseyenko, Vladimir;
Tjulandin, Sergei

Publication type:

Article

Cyclin-dependent kinase (CDK) 4/6 inhibition in non-small cell lung cancer with epidermal growth factor receptor (EGFR) mutations.

Published in:

Investigational New Drugs, 2023, v. 41, n. 2, p. 183, doi. 10.1007/s10637-023-01337-8

By:

Osoegawa, Atsushi;
Takumi, Yohei;
Hashimoto, Takafumi;
Nakatsuji, Shotaro;
Hori, Mayu;
Sakai, Mayu;
Karashima, Takashi;
Abe, Miyuki;
Miyawaki, Michiyo;
Sugio, Kenji

Publication type:

Article

Safety and anti-tumor activity of lisavanbulin administered as 48-hour infusion in patients with ovarian cancer or recurrent glioblastoma: a phase 2a study.

Published in:

Investigational New Drugs, 2023, v. 41, n. 2, p. 267, doi. 10.1007/s10637-023-01336-9

By:

Joerger, Markus;
Hundsberger, Thomas;
Haefliger, Simon;
von Moos, Roger;
Hottinger, Andreas F.;
Kaindl, Thomas;
Engelhardt, Marc;
Marszewska, Michalina;
Lane, Heidi;
Roth, Patrick;
Stathis, Anastasios

Publication type:

Article

In vitro effects of gamma-secretase inhibition in HPV-positive and HPV-negative head and neck squamous cell carcinoma.

Published in:

Investigational New Drugs, 2023, v. 41, n. 2, p. 193, doi. 10.1007/s10637-023-01334-x

By:

Varatanovic, Sara;
Maier, Tobias;
Al-Gboore, Sega;
Stoiber, Stefan;
Kandathil, Sam Augustine;
Quint, Clemens;
Brennus, Charlotte;
Heiduschka, Gregor;
Kadletz-Wanke, Lorenz;
Brkic, Faris F.

Publication type:

Article

Effect of a moderate CYP3A inducer efavirenz on the pharmacokinetics of fuzuloparib: An open-label, fixed sequence study in Chinese healthy male subjects.

Published in:

Investigational New Drugs, 2023, v. 41, n. 2, p. 276, doi. 10.1007/s10637-023-01331-0

By:

Hu, Linlin;
Dou, Ting;
Sun, Qiuyue;
Tang, Lu;
Cai, Mingmin;
Qian, Wei;
Wang, Huiping

Publication type:

Article

A phase I dose-escalation study of SYHA1813, a VEGFR and CSF1R inhibitor, in patients with recurrent High-Grade Gliomas or Advanced Solid Tumors.

Published in:

Investigational New Drugs, 2023, v. 41, n. 2, p. 296, doi. 10.1007/s10637-022-01325-4

By:

Kang, Zhuang;
Li, Shenglan;
Lin, Yi;
Li, Yongsheng;
Mao, Ying;
Zhang, Jing;
Lei, Ting;
Wang, Haidan;
Su, Yangzhi;
Yang, Yang;
Qiu, Jingbo;
Li, Wenbin

Publication type:

Article

Complete Response to tenalisib and romidepsin with long-term maintenance using tenalisib monotherapy in a patient with relapsed and refractory sézary syndrome.

Published in:

Investigational New Drugs, 2023, v. 41, n. 2, p. 350, doi. 10.1007/s10637-022-01315-6

By:

Nguyen, Christopher N.;
Iyer, Swaminathan P.;
Duvic, Madeleine;
Barde, Prajak J.;
Nair, Ajit;
Routhu, Kasi Viswanath;
Huen, Auris O.

Publication type:

Article